Insider Selling: Nektar Therapeutics (NKTR) SVP Sells 3,461 Shares of Stock

Nektar Therapeutics (NASDAQ:NKTR) SVP Stephen K. Doberstein sold 3,461 shares of Nektar Therapeutics stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $31.37, for a total transaction of $108,571.57. Following the sale, the senior vice president now owns 95,913 shares of the company’s stock, valued at $3,008,790.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of NKTR traded up $0.68 during mid-day trading on Friday, reaching $32.02. The company’s stock had a trading volume of 1,480,671 shares, compared to its average volume of 1,752,666. The firm has a market cap of $5.91 billion, a price-to-earnings ratio of 8.47 and a beta of 2.96. The company has a debt-to-equity ratio of 0.21, a quick ratio of 14.83 and a current ratio of 14.94. Nektar Therapeutics has a 52 week low of $29.22 and a 52 week high of $92.17.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.03. The firm had revenue of $28.22 million during the quarter, compared to analyst estimates of $25.45 million. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. During the same period in the previous year, the business posted ($0.60) EPS. As a group, equities research analysts predict that Nektar Therapeutics will post -3.14 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP increased its stake in shares of Nektar Therapeutics by 20.7% in the first quarter. Wellington Management Group LLP now owns 12,961,558 shares of the biopharmaceutical company’s stock worth $435,507,000 after buying an additional 2,220,193 shares during the period. FMR LLC increased its stake in shares of Nektar Therapeutics by 8.5% in the fourth quarter. FMR LLC now owns 25,961,520 shares of the biopharmaceutical company’s stock worth $853,355,000 after buying an additional 2,041,954 shares during the period. Norges Bank purchased a new position in shares of Nektar Therapeutics in the fourth quarter worth $63,723,000. Vanguard Group Inc increased its stake in shares of Nektar Therapeutics by 3.6% in the third quarter. Vanguard Group Inc now owns 18,922,650 shares of the biopharmaceutical company’s stock worth $1,153,525,000 after buying an additional 660,907 shares during the period. Finally, Deutsche Bank AG increased its stake in shares of Nektar Therapeutics by 131.6% in the fourth quarter. Deutsche Bank AG now owns 947,004 shares of the biopharmaceutical company’s stock worth $31,125,000 after buying an additional 538,170 shares during the period. Hedge funds and other institutional investors own 94.90% of the company’s stock.

Several equities research analysts have issued reports on NKTR shares. BidaskClub upgraded shares of Nektar Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, April 5th. BMO Capital Markets initiated coverage on shares of Nektar Therapeutics in a report on Friday, February 22nd. They issued an “outperform” rating and a $75.00 price objective for the company. Mizuho restated a “buy” rating and issued a $81.00 price objective on shares of Nektar Therapeutics in a report on Friday, March 1st. HC Wainwright restated a “hold” rating and issued a $47.00 price objective on shares of Nektar Therapeutics in a report on Tuesday, February 19th. Finally, TheStreet upgraded shares of Nektar Therapeutics from a “d+” rating to a “c” rating in a report on Thursday, February 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $69.73.

WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2019/05/17/insider-selling-nektar-therapeutics-nktr-svp-sells-3461-shares-of-stock.html.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Featured Article: How to Profit and Limit Losses With Stop Orders

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply